Neurocrine Biosciences Stock Net Asset
NBIX Stock | USD 139.83 3.20 2.24% |
Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.
Neurocrine | Net Asset |
Neurocrine Biosciences Company Net Asset Analysis
Neurocrine Biosciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Neurocrine Biosciences Net Asset | 3.25 B |
Most of Neurocrine Biosciences' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neurocrine Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurocrine Biosciences is extremely important. It helps to project a fair market value of Neurocrine Stock properly, considering its historical fundamentals such as Net Asset. Since Neurocrine Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurocrine Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurocrine Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition |
Neurocrine Total Assets
Total Assets |
|
Based on the recorded statements, Neurocrine Biosciences has a Net Asset of 3.25 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Neurocrine Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.Neurocrine Biosciences is currently under evaluation in net asset category among related companies.
Neurocrine Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Neurocrine Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurocrine Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurocrine Biosciences' value.Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.4 M | Dodge & Cox | 2023-12-31 | 1.3 M | Dsm Capital Partners Llc | 2023-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.2 M | Deerfield Management Co | 2023-09-30 | 1.2 M | Wellington Management Company Llp | 2023-12-31 | 1.2 M | Rock Springs Capital Management Lp | 2023-12-31 | 1.2 M | Brown Advisory Holdings Inc | 2023-12-31 | 1.1 M | Armistice Capital, Llc | 2023-12-31 | 1 M | Blackrock Inc | 2023-12-31 | 13.6 M | Vanguard Group Inc | 2023-12-31 | 9.7 M |
Neurocrine Fundamentals
Return On Equity | 0.13 | ||||
Return On Asset | 0.0878 | ||||
Profit Margin | 0.13 % | ||||
Operating Margin | 0.29 % | ||||
Current Valuation | 13.12 B | ||||
Shares Outstanding | 100.58 M | ||||
Shares Owned By Insiders | 0.99 % | ||||
Shares Owned By Institutions | 94.72 % | ||||
Number Of Shares Shorted | 2.02 M | ||||
Price To Earning | 202.90 X | ||||
Price To Book | 6.07 X | ||||
Price To Sales | 7.18 X | ||||
Revenue | 1.89 B | ||||
Gross Profit | 1 B | ||||
EBITDA | 416.1 M | ||||
Net Income | 249.7 M | ||||
Cash And Equivalents | 799.4 M | ||||
Cash Per Share | 8.31 X | ||||
Total Debt | 428.4 M | ||||
Debt To Equity | 0.18 % | ||||
Current Ratio | 2.48 X | ||||
Book Value Per Share | 22.61 X | ||||
Cash Flow From Operations | 389.9 M | ||||
Short Ratio | 2.26 X | ||||
Earnings Per Share | 2.47 X | ||||
Price To Earnings To Growth | 0.44 X | ||||
Target Price | 153.29 | ||||
Number Of Employees | 1.4 K | ||||
Beta | 0.28 | ||||
Market Capitalization | 14.39 B | ||||
Total Asset | 3.25 B | ||||
Retained Earnings | (157.1 M) | ||||
Working Capital | 952.2 M | ||||
Current Asset | 384.07 M | ||||
Current Liabilities | 25.71 M | ||||
Net Asset | 3.25 B |
About Neurocrine Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Neurocrine Biosciences Investors Sentiment
The influence of Neurocrine Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Neurocrine. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Neurocrine Biosciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurocrine Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurocrine Biosciences' short interest history, or implied volatility extrapolated from Neurocrine Biosciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Neurocrine Biosciences Piotroski F Score and Neurocrine Biosciences Altman Z Score analysis. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.47 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.